CIK 0001347178
- Accelerated filer
Vanda Pharmaceuticals Inc.
Sign in to watch- Ticker
- VNDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 030491827
- Phone
- +1 202-734-3400
- Business address
- 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
- 4 Open-market sale President and CEO sold 125,252 shares at an average $13.04 ($1,633,510)
- 4 Open-market sale SVP, Chief Marketing Officer sold 3,710 shares at $11.08 ($41,109)
- 4 Open-market sale SVP & General Counsel sold 3,684 shares at $11.81 ($43,526)
- 4 Open-market sale Chief Corp. Affairs Officer sold 7,200 shares at $11.81 ($85,018)
- 4 Grant or award SVP, CFO & Treasurer acquired 17,344 shares (grant or award)
- 4 Open-market sale Chief Corp. Affairs Officer sold 7,313 shares at $10.62 ($77,631)
- 4 Grant or award Director acquired 5,000 shares (grant or award)
- 4 Grant or award Director acquired 5,000 shares (grant or award)
- 4 Grant or award Director acquired 5,000 shares (grant or award)
- 4 Grant or award Director acquired 5,000 shares (grant or award)
- 4 Grant or award Director acquired 5,000 shares (grant or award)
- 4 Open-market sale Director sold 9,677 shares at $11.50 ($111,286)
- 4 Open-market sale Director sold 10,129 shares at $11.04 ($111,806)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale SVP & General Counsel sold 4,385 shares at an average $10.36 ($45,440)
- 4 Open-market sale SVP & Chief Commercial Officer sold 1,450 shares at $10.18 ($14,755)
- 4 Open-market sale President and CEO sold 15,580 shares at an average $10.70 ($166,756)
- 4 Open-market sale EVP & Chief Financial Officer sold 18,857 shares at an average $10.36 ($195,446)
- 4 Open-market sale SVP, Business Development sold 17,758 shares at an average $10.23 ($181,670)
- 4 Grant or award SVP & General Counsel acquired 30,000 shares (grant or award)
Page 8 of 29 · 579 filings